A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of
ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor
efficacy of ES101 in advanced malignant thoracic tumors, including NSCLC and SCLC.